Oral Norovirus Vaccine: Vaxart announces positive pre-clinical data

Vaxart, Inc., a privately held, clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced positive results demonstrating that the company's oral norovirus vaccine candidate elicited substantial systemic and mucosal immune responses to norovirus in preclinical studies. The data were presented at the 16th Annual World Vaccine Congress ["]